Study of Efficacy of Tofacitinib, a JAK Inhibitor in the Treatment of Alopecia Areata

Abstract

Alopecia Areata (AA) is an autoimmune condition causing patchy hair loss on the scalp, beard, eyebrows, and, in rare instances, even the body hair. Tofacitinib, a JAK3 inhibitor, is a promising treatment for severe and resistant instances of AA/totalis/universalis. The aim of our study is to show the effectiveness of oral tofacitinib in the treatment of alopecia universalis (AU). In our study 8 patients with resistant AA were included after informed consent and proper pre JAK evaluation tests.  All 8 patients received tofacitinib orally at doses ranging from 5 mg twice day, with follow-ups every three weeks. Hair analysis including the basic profile, hormonal, hair test, Trichrogram and Dermascopy were used to assess the effectiveness. Patients were followed up on for 8 months after therapy ended to look for any signs of a disease recurrence. Each of our eight patients responded remarkably to oral tofacitinib. Patients were examined and the results were assessed every three weeks. All of the patients exhibited noticeable hair regrowth after 10 weeks. Our results suggested that tofacitinib significantly reduced AU in our patients without causing any serious negative side effects. To establish safety and validate efficacy, we advise performing further controlled study.